



Disruption of the PACAP gene promotes medulloblastoma in *ptc1* mutant mice

Vincent Lelievre^{a,e,f}, Akop Seksenyan^a, Hiroko Nobuta^a, William H. Yong^b, Seririthanar Chhith^a, Pawel Niewiadomski^a, Joseph R. Cohen^a, Hongmei Dong^a, Avegail Flores^a, Linda M. Liau^{c,e}, Harley I. Kornblum^{a,d,e}, Matthew P. Scott^g, James A. Waschek^{a,e,*}

^a Department of Psychiatry and Biobehavioral Research/Mental Retardation Research Center, University of California at Los Angeles, USA

^b Department of Pathology and Laboratory Medicine, University of California at Los Angeles, USA

^c Division of Neurosurgery, Department of Surgery, University of California at Los Angeles, USA

^d Molecular and Medical Pharmacology, University of California at Los Angeles, USA

^e Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, USA

^f Institute of Cellular and Integrative Neurosciences (INCI), UMR7168/LC2 CNRS-Université Louis Pasteur, Strasbourg, France

^g Departments of Developmental Biology and Genetics, Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA

Received for publication 31 May 2007; revised 10 October 2007; accepted 22 October 2007

Abstract

Hedgehog (Hh) proteins and cAMP-dependent protein kinase A (PKA) generally play opposing roles in developmental patterning events. Humans and mice heterozygous for mutations in the sonic hedgehog (Shh) receptor gene *patched-1* (*ptc1*) have an increased incidence of certain types of cancer, including medulloblastoma (MB), a highly aggressive tumor of the cerebellum. Despite the importance of PKA in Hh signaling, little is known about how PKA activity is regulated in the context of Hh signaling, or the consequences of improper regulation. One molecule that can influence PKA activity is pituitary adenylyl cyclase-activating peptide (PACAP), which has been shown to regulate cerebellar granule precursor proliferation *in vitro*, a cell population thought to give rise to MB. To test for a PACAP/Hh interaction in the initiation or propagation of these tumors, we introduced a PACAP mutation into *ptc1* mutant mice. Deletion of a single copy of PACAP increased MB incidence approximate 2.5-fold, to 66%, thereby demonstrating that PACAP exerts a powerful inhibitory action on the induction, growth or survival of these tumors. Tumors from PACAP/*ptc1* mutant mice retained PACAP receptor gene expression, and exhibited superinduction of Hh target genes compared to those from *ptc1*+/- mice. Moreover, PACAP inhibited proliferation of cell lines derived from tumors in a PKA-dependent manner, and inhibited expression of the Hh target gene *gli1*. The results provide genetic evidence that PACAP acts as a physiological factor that regulates the pathogenesis of Hh pathway-associated MB tumors.

© 2007 Elsevier Inc. All rights reserved.

Keywords: PACAP; Hedgehog; Medulloblastoma; Patched; Cerebellum; Protein kinase A; Pituitary adenylyl cyclase activating peptide; PKA; cAMP; Brain tumor

Introduction

Studies in flies, fish, frogs, rodents and humans indicate that hedgehog (Hh) signaling is essential for the proper patterning and growth of many organs (Fukuda and Yasugi, 2002; Lum and Beachy, 2004; Poh et al., 2002). Cyclic AMP-dependent

protein kinase A (PKA) opposes Hh action in many of these processes, causing the repression of Hh target genes until Hh signal relieves the repression. For example, loss of PKA in *Drosophila* mutants lacking Hh results in the activation of Hh target genes and induction of patterning events that are normally dependent on Hh (Li et al., 1995). Conversely, overexpression of PKA counteracts the effects of Hh pathway activation (Li et al., 1995). PKA is believed to interfere with Hh action in *Drosophila* by phosphorylating and thereby priming the transcription factor cubitus interruptus (CI) for subsequent phosphorylation and processing into a repressor form (Aza-

* Corresponding author. 635 Charles E. Young Dr. South, University of California at Los Angeles, Los Angeles, CA 90095, USA. Fax: +1 310 206 5061.

E-mail address: jwaschek@mednet.ucla.edu (J.A. Waschek).

Blanc et al., 1997; Chen et al., 1999). On the other hand, PKA-dependent phosphorylation of Smo has been shown to promote the Hh pathway in *Drosophila* (Jia et al., 2004). Although the *Drosophila* PKA-phosphorylation sites on Smo are not conserved in vertebrates, studies in chicks indicate that PKA may have other Hh promoting actions in vertebrates (Tiecke et al., 2007). In any case, many aspects of the PKA antagonism of the Hh pathway are conserved in vertebrates. For example, overexpression of a dominant inhibitory form of PKA in the mouse neural tube mimicked overexpression of Shh (Epstein et al., 1996), and conversely, expression of a constitutively active form of PKA in zebrafish blocked the effects of Shh overexpression (Hammerschmidt et al., 1996). However, the mechanisms that regulate PKA activity so that Hh signal transduction is kept at proper levels remain largely unknown in flies and vertebrates.

Mutations resulting in loss of function of human Shh elicit severe abnormalities of the developing brain, a condition called holoprosencephaly. Conversely, mutations that cause derepression of Shh target genes are associated with multiple cancer types including basal cell nevus syndrome (also called Gorlin syndrome) as well as MB. Such mutations have arisen in genes encoding the Shh receptor/tumor suppressor Patched-1 (Ptc1), the signal-transducing transmembrane protein Smoothed (Smo), and the downstream intracellular signaling protein Suppressor of fused (SuFu).

MB is the most common pediatric brain tumor and its recurrence is nearly always fatal. An understanding of the pathogenesis and growth regulatory mechanisms of this tumor is greatly needed, as is the development and optimization of appropriate animal models. Mice with targeted deletions of the *ptc1* gene are an excellent model for studying Hh pathway-associated pathology. *ptc1* mutant mice die on about embryonic day 9–10.5 due to multiple defects, including massive neural tube overgrowth (Goodrich et al., 1997). Heterozygous animals, however, develop relatively normally *in utero*, but have a significant incidence of a specific panel of tumors including MB, a phenotype similar to that of humans with hereditary *ptc1* mutations (Gorlin's syndrome).

PKA activity is regulated by a number of different mechanisms (Baillie et al., 2005), any of which might impinge on Hh signal transduction. In order to understand better how PKA might influence cerebellum tumorigenesis, we have begun to examine the possible role of a small peptide, pituitary adenyl cyclase-activating peptide (PACAP), which is known to regulate PKA in tissues expressing its receptor. We recently demonstrated in rodents that mRNAs for the PACAP receptor PAC₁ and the Shh receptor Ptc1 are colocalized in the embryonic hindbrain ventricular zone (VZ), and in the postnatal external granule layer (EGL) of the cerebellum (Nicot et al., 2002; Waschek et al., 1998). These are the two germinal centers thought to give rise to MB in humans. PACAP has putative growth factor-like actions (Vaudry et al., 2000; Waschek, 2002) and is potentially supplied to cells in these centers by post-mitotic neurons in the developing hindbrain (Vaudry et al., 2000) and Purkinje cells in the developing cerebellum (Nielsen et al., 1998). We showed that PACAP

inhibits the expression of Shh target genes in embryonic hindbrain cultures (Waschek et al., 1998) and counteracts the proliferative actions of Shh in neuronal precursor cultures derived from the EGL (Nicot et al., 2002). These data set the stage for investigating if loss of PACAP might affect the incidence and/or growth rate of MB tumors in *ptc1*^{+/-} mice. Here we investigated the incidence, onset, and gene expression patterns in MB tumors in *ptc1*^{+/-} that have a targeted deletion in the PACAP gene.

Materials and methods

Mouse housing conditions

Mice were housed according UCLA Institutional Guidelines including standard light–dark cycles with food and water ad libitum. All mice were daily monitored for signs of illness or tumor effects.

PACAP and *ptc1* mutant mice

The generation of mice with targeted mutations in the PACAP and *ptc1* genes were previously described (Colwell et al., 2004; Goodrich et al., 1997). All animals used in the present study were backcrossed for at least six generations to a C57BL/6J genetic background. *Ptc1* heterozygous (Hz) mice were initially bred with PACAP Hz or PACAP null mice to generate *ptc1* and *ptc1*/PACAP double heterozygous (DH) mutants. Mice used for the analyses were generated by interbreeding these DH mice or by breeding either *ptc1*^{+/-} or DH male mice with female PACAP^{+/-} mice. Genotyping by PCR (Colwell et al., 2004; Goodrich et al., 1997) was performed at 6 weeks of age.

MB assessment

Mice were monitored daily for clinical signs of MB, such as lethargy, ataxia, balance defects, dehydration, and reduced grooming. When animals exhibited clinical signs, food (pellets and apple) was directly provided to animals to extend life span. When unable to take food, animals were sacrificed and autopsied. If presence of MB was confirmed, time of sacrifice was considered equivalent to date of death. The mean date of incidence was calculated using a non-linear regression analysis (sigmoid curve with variable slope) and performed using GraphPad™ Prism4 software.

Characterization of tumors

Tumors collected from ten *ptc1*^{+/-} and ten DH mice were fixed in 4% paraformaldehyde, paraffin-embedded, and sectioned at 6 μm. Sections were deparaffinized in two xylene baths and rehydrated in decreasing concentrations of alcohol baths. A standard hematoxylin and eosin staining was conducted on some of these sections. For immunohistochemistry, antigens were retrieved by boiling the sections in a solution containing 0.8 mM citric acid and 7 mM sodium citrate, adjusting pH 6.0 for 20 min and cooling for an additional 20 min. Following endogenous peroxidase inactivation with 3% hydrogen peroxide solution for 10 min, sections were rinsed in PBS and blocked in PBS containing 5% normal goat serum. Primary antibodies against synaptophysin (polyclonal, dilution 1:100; Santa Cruz) and GFAP (polyclonal, dilution 1:200; Neo Markers) were diluted in the blocking solution and incubated overnight at 4 °C. After washes in PBS, biotinylated anti-rabbit secondary antibody (Vector) was diluted in PBS (1:200) and incubated for 30 min at room temperature. After additional washes in PBS, slides were incubated in avidin–biotin peroxidase solution (Vectastain ABC kit; Vector) for 30 min at room temperature. Sections were visualized using DAB substrate solution prepared from liquid DAB kit (Biogenex). Sections were then counterstained with DAPI for nuclear visualization, washed in water, dehydrated in increasing concentrations of alcohol baths, xylene-treated and coverslipped.

Ectopic cerebellar lesions

Postnatal day 28 mice were transcardially perfused with 4% paraformaldehyde. Brains were postfixed in 4% paraformaldehyde for 2 h, cryoprotected, and sectioned at 12 μ m. After blocking, immunohistochemistry was performed with a Ki-67 (polyclonal, dilution 1:250; Vector) incubated for 1 h at 37 °C. Following washes, secondary antibody (Cy3-conjugated anti-rabbit; Jackson Immuno Research) was incubated for 45 min at room temperature. After additional washes, sections were coverslipped with Vectashield Mounting Media (Vector) containing DAPI for nuclear visualization. For *in situ* hybridization for PAC₁ gene expression was carried out with ³³P as described (Waschek et al., 1998).

Isolation of MB cell lines

In a subset of animals showing clinical signs for MB, cerebella were dissected under strict aseptic conditions. Tumors were carefully separated from normal cerebellar tissue. Half of the tumor was quickly homogenized in guanidinium isothiocyanate solution (GnTC) solution prior to RNA isolation. The second half was dissociated in trypsin/EDTA solution for 10 min. Trypsin was then inactivated by addition of several volumes of DMEM culture medium containing 20% inactivated fetal bovine serum (FBS). After centrifugation, the cell suspension was placed into a tissue culture flask in DMEM medium supplemented with 10% inactivated FBS. Cultures were kept at 37 °C in 5% CO₂ controlled atmosphere. Medium was replaced every week, until growing cell clusters appeared. Growing cells were expanded and grown in monolayer conditions, and passaged a few times prior to freezing in liquid nitrogen.

Isolation of granular cell progenitors (GC)

Cerebella were carefully and aseptically dissected from WT mice. GC isolation was performed using a Percoll gradient as previously described (Tao et al., 1997). Cells were cultured for 3 h to allow contaminating cells to attach. GC were then removed using gentle pipetting and subjected to RNA extraction as described (Chomczynski and Sacchi, 1987).

Drugs

PACAP-38, forskolin, and H89 were obtained from Calbiochem.

β -galactosidase staining

Cells were fixed in 0.2% glutaraldehyde for 5 min, washed in PBS, then incubated overnight at 37 °C in Xgal buffer (5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside; Xgal) at a final concentration of 0.4 mg/ml (made from a 40 mg/ml stock in dimethylformamide), with 4 mM K₃Fe(CN)₆, 4 mM K₄Fe(CN)₆·6H₂O, and 2 mM MgCl₂ in PBS.

Cyclic AMP assay

A commercial radioimmunoassay kit from Amersham used. Dissociated cells were seeded in 24-well tissue culture plates at the initial density of 50,000 cells/well. 48 h later, the culture medium was replaced by 460 μ l of serum-free medium containing 1 mM of IBMX (Sigma). About 20 min later, 40 μ l of peptides (100 \times), vehicle (DMSO) or drug (forskolin, 100 \times) was added for another 20 min. Culture medium was promptly removed by aspiration and wells rinsed once with 1 ml of cold PBS, prior to cell extraction with 500 μ l of 6% TCA after a 10-s sonication. Extracts were transferred into 1.5-ml Eppendorf tubes and frozen at -80 °C for 24 h. Samples were finally dried out in a SpeedVac apparatus and pellets reconstituted in 500 μ l of 0.05 M acetate buffer. Diluted samples were analyzed for cAMP contents according to the manufacturer's protocol (Amersham) and cAMP was quantified using a cAMP standard curve performed concomitantly.

PKA assay

MB #57 cells were plated at a density of 15000 cells/cm² and left in culture for 48 h in DMEM media containing penicillin/streptomycin/glutamine

and 10% FBS. They were switched to media containing 1% serum 2 h before the start of the experiment. The cells were incubated for 1 h with H89 (3 μ M) or DMSO as a control, and then forskolin (20 μ M) or DMSO was added for another 1 h. The cells were washed in PBS, harvested by scraping off, and flash frozen in liquid nitrogen. The cells were lysed in the NP-40 lysis buffer containing protease and phosphatase inhibitors for 30 min on ice, and then debris was removed by centrifugation. The protein extracts were subjected to PAGE on 7% polyacrylamide gels, and following transfer to PVDF membrane, to Western blotting using the following primary antibodies: rabbit anti-phospho-PKA substrate (1:5000; Cell Signaling), mouse anti-GAPDH (1:2500; Imgenex).

Proliferation studies

In vitro thymidine incorporation on MB cells in culture was performed using the trichloroacetic acid (TCA) precipitation method. Dissociated tumor cells were seeded in 24-well tissue culture plates at the initial density of 50,000 cells/well and cultured in DMEM medium supplemented with 2% of heat-inactivated FCS (Gibco-Brl/Life Technology) and a cocktail of penicillin/streptomycin antibiotics. 48 h later, medium was replaced with fresh medium for 2 h prior to cell treatments with peptides and/or drugs for 6 h. Drug treatments (5 μ l/500 μ l total volume) were performed using extemporarily prepared 100 \times stock solutions. About 30 min later, ³H-thymidine (NEN/Perkin-Elmer), 1 μ Ci/well, was then added. Cells were harvested 8 h later. Cell cultures were washed with 500 μ l/well of PBS then lysed in 500 μ l of 0.5 M NaOH. Cell extracts were transferred into 2-ml Eppendorf tubes and supplemented with 500 μ l of cold 20% TCA. DNA precipitation was allowed for 20 min on ice then samples were centrifuged at 20,000 \times g, for 20 min at 4 °C. Supernatants were aspirated and the DNA-containing pellets washed with 500 μ l of 10% TCA. After a 10-min centrifugation, pellets were finally reconstituted in 500 μ l of 0.1 M NaOH and transferred into scintillation vials while incorporated radioactivity was counted on a scintillation counter (Beckman) using 5 ml of Aquasafe™ scintillation cocktail (Wallac). Cell proliferation by direct cell counting in other experiments was performed as previously described (Lelievre et al., 2000) with MB cells seeded at the initial density of 5000 cells/ml into 24-well tissue culture dishes and grown in DMEM medium supplemented with 1% FCS (Invitrogen). After 24 h, PACAP or vehicle was added daily at a final concentration of 10 nM, an equivalent amount of vehicle was added to control wells.

Competitive RT-PCR

The PAC₁ primer set was similar to the one used in a previous study (Nicot et al., 2002): sense primer, GGATGCTGGGATATGAATGACAG CACAGC, which recognized the sequences 1035–1064 of the mouse cDNA (D82935) and reverse primer, CCTTCCAGCTCCTCCATTCTCT, which recognized the sequences 1495–1472 and 1466–1452 of the same cDNAs. This target sequence was chosen because it may contain additional cassettes corresponding to previously reported splice variants (Spengler et al., 1993). To quantify gene expression between samples, we included a set of 18S primers/competimer from Ambion. To ensure linear amplification for all the genes throughout the PCR cycles, a 1:7 ratio of 18S primer/competimer was determined. PCR was run for 35 cycles using a 3-step procedure (30-s denaturation at 96 °C, 40-s annealing at 58 °C and finally a 40-s extension at 72 °C). Samples were run on Nu-sieve 3% agarose gels. Gel pictures were shot using a Geldoc™ imaging system from Bio-Rad. Specificities of the different PCR amplifications were ultimately confirmed by sequencing.

Real-time RT-PCR

mRNAs encoding the genes of interest were first analyzed for secondary structure using M-fold software. Portions of sequences lacking significant secondary structure were imported into oligo6 software to design highly stringent primer sets. Ultimately, these primers were blasted in cDNA databases to ensure their specificity. For *ghil*, we chose the following oligonucleotides: 5'–ATCTCTCTTCTCTCTCTCC–3'OH and 5'–CGAGCCTGGCATCAGAA–3'OH, as

sense and antisense primers, respectively. PCR amplification resulted in the specific formation of a 95-bp sequence corresponding to the region 356–449 of the previously published sequence of mouse *gli1* mRNA (NM101296). For *gli3*, 5′-GATCCATCTCCTATTCTCCA-3′OH and 5′-GATCCTAATGAAGGG CAAGTC-3′OH were used. The amplified 83-bp sequence corresponded to the 616–699 region of the published MN008130 sequence. For *Bmi1*, the following primer set 5′-TGTGT GGAGGGTACTTCATT-3′OH and 5′-AGGACAA-TACTTGCTGGTCTC-3′OH was used. This amplified a unique PCR fragment of 100 bp corresponding to the portion 383–486 of the published *Bmi1* gene (MUSBMI1B). For the mouse homologue of the *Mushashi* (*Msh1*) gene (NML008629), 5′-TCAAGCTGCCAGAAGATGCTC-3′OH and 5′-GGA-GAAGCGGGGACT CTGC-3′OH were used to specifically amplify a 84-bp sequence located in position (494–579). For *N-myc*, 5′-GGATGATCGCAA-GAACCCAG-3OH and 5′-GTCATCTTCGTCGGG TAGAA-3OH primer set selectively amplified a unique 70-bp band corresponding to the region 72–172 of the published *N-myc* sequence (M36277) whereas the following primer set 5′-ATCTACATCAACGCTCTGTCTG-3OH and 5′-AAGGT-GATGGTGGTCATTTTT-3OH spanned a 99-bp amplicon of the region 801–899 of the granule cell progenitor marker *Math1* gene (D43694). To standardize the experiments we designed, using the same approach a primer set for the mouse β_2 -microglobulin (*β_2 MG*) gene (5-CCGGCTTGTATGCTATC-3′OH and 5-AGTTCATGTTCCGGCTTC-3′OH, as sense and anti-sense, respectively) and another set for glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*: 5′-GG-CCTTCCGTGTTCTAC-3′OH and 5′-TGTCATCATACTTGGCAGGTT-3′OH). These oligonucleotides amplified an 87-bp region encoding the nucleotides 99–185 of the published sequence (MM2BMR) and an 80-bp piece spanning the area 1093–1173 of published *GAPDH* (XM111622) mRNA, respectively. Real-time PCR was set up using Syber Green-containing supermix from Bio-Rad, for 50 cycles of a 3-step procedure including a 20-s denaturation at 96 °C, a 15-s annealing at 60–62 °C, followed by a 20-s extension at 72 °C. Amplification specificity was assessed by melting curve and sequencing analyses. Quantification of each PCR samples was made using standard curves made from serial dilutions of control samples or of the corresponding cDNA cloned into PCR II vector. Differences between samples were calculated as the difference between the specific ratios (gene/ *β_2 MG* or gene/*GAPDH*) calculated for each individual sample. As in competitive RT-PCR, specificities of the different PCR amplifications were ultimately confirmed by sequencing.

Results

Generation of *ptc1*^{+/-} PACAP^{+/-} double mutants (DH) and assessment of *Shh* pathway activity in the cerebellum

We generated PACAP knockout (KO) mice on a C57BL/6J background, and confirmed loss of PACAP production by radioimmunoassay (Colwell et al., 2004). Consistent with that observed with other PACAP KO strains (Gray et al., 2001; Hashimoto et al., 2001), significant numbers of PACAP KO mice die before genotyping. However, heterozygous and surviving PACAP^{-/-} mice show no subsequent increased morbidity under normal housing conditions. We bred backcrossed PACAP KO males with C57BL/6-backcrossed *ptc1*^{+/-} females (Goodrich et al., 1997) to generate the first generation of DH mutants. These animals were fertile and were subsequently interbred to generate the animals used in the present study. Litters of DH × DH breedings were genotyped at 6 weeks of age to determine the survival of the various genotypes (Table 1). No *ptc1*^{-/-} and few PACAP^{-/-} mice were present at the time of genotyping among 130 offspring obtained from 26 matings.

To determine if the relative loss of PACAP in PACAP^{+/-} mice resulted in increased Hh pathway activity in the cerebella of asymptomatic *ptc1*^{+/-} mice, we determined the expression

Table 1

Genotypes of 130 mice derived from interbreedings of PACAP/*ptc1* double heterozygous mice

		PACAP genotype		
		+/+	+/-	-/-
<i>ptc1</i> genotype	+/+	14	27	1
	+/-	33	52	1 ^a
	-/-	0	0	0

Genotyping was performed 6 weeks after birth.

^a This mouse died of unknown causes within 1 week of DNA sampling.

levels of the *Shh* target gene *gli1* in the cerebella of asymptomatic *ptc1*^{+/-} and DH mice at 1 and 6 months of age. We found that *gli1* mRNA levels were significantly increased in the cerebella of 1- and 6-month-old asymptomatic *ptc1*^{+/-} compared to wild-type mice, and increased even further in PACAP/*ptc1* double heterozygous (DH) mice (Fig. 1A). However, the levels of *gli1* gene expression in PACAP mutants (HZ or null) with both *ptc1* alleles intact were not elevated over that of wild type control mice (Fig. 1B). Reciprocally, levels of PACAP gene expression were not affected by monoallelic loss of *ptc1*, but were reduced, as expected, in PACAP^{+/-} and DH mice (Fig. 1C). These data suggest that *Ptc1* and PACAP mutually inhibit *Shh* pathway activity in asymptomatic animals.

MB induction and cancer survival

To determine whether the incidence of MB tumors increases in *ptc1*^{+/-} mice that also lack a PACAP allele, the incidence of MB over a 1-year period was determined in mice derived from DH × DH matings and from matings of PACAP^{+/-} females with either *ptc1*^{+/-} or DH males. A total of 77 *ptc1* heterozygotes and 73 *ptc1*/PACAP DH mutants were analyzed. Mice were monitored on a daily basis, and the dates of death or appearance of neurological symptoms and subsequent sacrifice were recorded. The presence or lack of MB was determined by autopsy. Deletion of a single copy of the PACAP gene strongly enhanced MB frequency in *ptc1* mutants (Fig. 2A). Indeed, a 66% rate of MB was observed in DH mice, reflecting a 2.5-fold increased incidence compared to *ptc1*^{+/-} mice. The onset of clinical signs of MB (lethargy, ataxia, etc.) was also shifted to an earlier stage in DH mice (Fig. 2B). The mean date of occurrence of symptoms was 6.2 months in *ptc1*^{+/-} control mutants, similar to that reported by others (Goodrich et al., 1997; Wetmore et al., 2000). The mean date of occurrence in DH mutants was 4.8 months, 6 weeks sooner than in *ptc1* mutants. The incidences were maintained when the data were segregated on the bases of parental breeding (not shown).

The incidence of rhabdomyosarcoma in both groups was small, as previously shown in mice with this *ptc1*^{+/-} mutation (Goodrich et al., 1997; Wetmore et al., 2000). Out of more than 200 PACAP^{-/-} mice generated in our colony for other studies, none developed MB, indicating that complete loss of PACAP is insufficient to induce this tumor.




Fig. 1. *Gli1* and PACAP gene expression in isolated cerebella from wild-type (WT), *ptc1*^{+/-}, PACAP^{+/-}, PACAP KO or *ptc1*/PACAP double mutant (DH) mice. (A) Comparison of *gli1* gene expression (as determined by quantitative real-time RT-PCR) in cerebella from WT 1- and 6-month-old wild type, *ptc1*^{+/-} and DH mice. Cerebella were dissected and examined under the stereomicroscope to exclude animals harboring obvious cerebellar abnormalities. Cerebella from *ptc1*^{+/-} mice and PACAP/*ptc1* DH exhibited significantly higher *gli1* gene expression than WT. Cerebella from DH mice exhibited significantly higher expression than those from *ptc1*^{+/-} mice. (B) *Gli1* gene expression levels in cerebella from 1-month-old WT, PACAP^{+/-}, PACAP^{-/-} and *ptc1* mutants showed no direct effect of PACAP gene disruption alone on Shh target gene expression. (C) PACAP gene expression in WT, *ptc1* and PACAP mutants showed no effect of *ptc1* mutation on PACAP gene expression. Values are mean±SEM ($n=7$ per group): * $p\leq 0.05$; ** $p<0.01$ (ANOVA).

Characterization of MB tumors in DH mice

To characterize the MB tumors in DH mice, we dissected, formalin-fixed, and paraffin-embedded ten tumors each from *ptc1*^{+/-} and DH mice. Similar to that reported in tumors from *ptc1*^{+/-} mice and from humans, tumors in DH mice were comprised of densely packed cells with pleomorphic, hyperchromatic carrot-shaped nuclei and with scant cytoplasm (Goodrich et al., 1997; Wetmore et al., 2000) (Fig. 3, top panel). Mitotic activity and occasional confluent areas of apoptosis were noted. By the criteria of Eberhart and colleagues, these tumors may be representative of moderately anaplastic human medulloblastomas (Berman et al., 2002). Tumors from either genotype lacked obvious nodularity (WHO schema (Kleihues et al., 1998)), similar that reported in *ptc1*^{+/-} tumors by others (Corcoran and Scott, 2001; Goodrich et al., 1997; Kimura et al., 2003; Wetmore et al.,

2000). Also similar to tumors from *ptc1* mutant mice (Wetmore et al., 2000) and human MB (Ellison, 2002), immunocytochemistry on DH tumors revealed varying degrees of synaptophysin and GFAP immunoreactivity (Fig. 3, bottom panels). In general, the staining for synaptophysin is extensive while the GFAP-positive cells are few and may represent reactive astrocytes. Analysis of tumors from 10 *ptc1*^{+/-} and 10 DH mice revealed no obvious differences in histological features on H&E staining or in patterns of synaptophysin or GFAP immunoreactivities.

PACAP receptor gene expression in hyperplastic regions of the EGL and MB tumors

We previously showed by *in situ* hybridization that mRNA for the PACAP-specific receptor PAC₁ co-localized with that of *ptc1* in the postnatal cerebellar EGL as well as in the




Fig. 2. Effect of PACAP gene disruption on the incidence of MB in *ptc1* mutants over 1 year. (A) Overall comparison between *ptc1*^{+/-} and *ptc1*/*PACAP* double heterozygous (DH) mutants revealed a 2.5-fold increase in medulloblastoma in the latter group. 77 and 73 mice were in the *ptc1*^{+/-} and DH groups, respectively. Statistical analysis using the χ^2 contingency test revealed significant differences between *ptc1* and DH groups at $p=0.019$. (B) Survival from medulloblastoma in *ptc1*^{+/-} animals vs. DH mutants. Double mutants exhibit an overall 6-week-earlier mean age of death from medulloblastoma than *ptc1*^{+/-} animals. The survival curves were created using the product limit method of Kaplan and Meier (GraphPad™ Prism4) and comparison of survival curves between *ptc1* and DH mutants was performed using the log rank test. Analysis revealed statistical differences at $p<0.0001$.

embryonic hindbrain ventricular zone. Given that one or both of these germinal zones are felt to give rise to MB, we were interested to know if PAC₁ gene expression was present in MB tumors that presented in these mice. RT-PCR analysis of eight tumors indicated that the PAC₁ gene was expressed in all tumors (Fig. 4A). Moreover, *in situ* hybridization showed that PAC₁ gene expression was present in patches of hyperplastic EGL at postnatal day 28 (Figs. 4B and C). These patches have been shown by others to persist in most *ptc1*^{+/-} animals for a few weeks after the EGL normally recedes, and have been proposed to represent premalignant lesions. Thus, PAC₁ gene expression is present in granule precursors at an early stage

and appears to persist in these cells as they develop into full tumors.

Expression of Hh target and other genes in MB samples

Our original hypothesis was that PACAP limits the activity of Shh in cerebellar precursors, and that loss of this inhibitory action might lead to higher hedgehog activity during the inductive and/or growth rate of these tumors. Shh pathway activity can be estimated by measuring the level of expression of Hh target genes. To determine if MB tumors in PACAP^{+/-} mice were associated with derepression of Shh pathway activity compared to those from *ptc1*^{+/-} mice, we compared the expression of Shh target genes from these groups of mice by real-time RT-PCR. These studies revealed that the expression of three Shh target genes, *gli1*, *N-myc* and *Bmi1*, was 2- to 5-fold higher in tumors from DH mice than in tumors from *ptc1*^{+/-} mice ($p<0.01$), and higher than in normal cerebellum (CB) and freshly isolated granular cell progenitors (GC) (Fig. 5), whereas *gli3* gene expression did not significantly differ in the two sets of tumors. Furthermore, gene expression in tumors from DH vs. *ptc1*^{+/-} mice was also increased for the Notch facilitator MSH1 ($p<0.01$), which is overexpressed in human MB tumors. The fact that the Shh target genes *gli1*, *N-myc* and *Bmi1* were expressed at higher levels in tumors from DH mutants than in those from *ptc1*^{+/-} mice suggests that the reduction of PACAP in double-mutant mice promotes Shh pathway activity in tumors, or that a lack of PACAP during their formation results in tumors with higher Shh activity.

Effects of PACAP on proliferation and gene expression in primary medulloblastoma cell lines

To determine if PACAP signaling remained intact in MB tumors, we established primary cell lines from six different tumors. Like the intact tumors (Fig. 4A), these cell lines expressed transcripts for the PAC₁ receptor (data not shown). All but one cell line responded to 10 nM PACAP with a significant reduction in DNA synthesis over an 8-h treatment period (Table 2). One of these cell lines (#57) was selected for further studies. PACAP potently and dose-dependently stimulated cAMP production in these cells (Fig. 6A), indicating that these cells expressed receptors that were functional coupled to cAMP production. PACAP also dose dependently inhibited DNA synthesis in these cells in a manner that was fully blocked by 3 μ M of the PKA antagonist H89 (Fig. 6B). This concentration of H89 was selected as the minimal dose which blocked the effect of forskolin on PKA activity in these cells (data not shown). PACAP inhibition on cell proliferation remained effective over a 3-week period of time when 10 nM PACAP were added daily (Fig. 6C). In addition to the antiproliferative action, PACAP inhibited gene expression for *gli1*, and reduced mRNA levels of *math-1*, a marker for undifferentiated granule cell precursors (Fig. 6D). The effects on gene expression were mimicked by the cAMP-inducing agent




Fig. 3. Histological characteristics, synaptophysin and GFAP immunoreactivities in representative tumors arising in *ptc1*/PACAP mutant mice. Top panel shows section of tumor from a *ptc1*/PACAP double mutant mouse stained with hematoxylin/eosin (H&E). Bottom panels show sections stained with antibodies for (left) synaptophysin (Syn) and (right) GFAP.

forskolin. These studies suggest that MB tumors in these mice retain the ability to respond to PACAP, and that the PACAP/PKA pathway might have use as a therapeutic target for MB tumors with elevated Hh activity.

Discussion

We describe here a new genetically engineered spontaneous brain tumor model which combines a HH pathway mutation (*ptc1*) with a PACAP gene mutation. A novel aspect of the model created and tested here is that it addresses the biology and pathogenesis of MB tumors in the context of their development and known signal transduction pathways. The receptor for PACAP is expressed along with the HH receptor in the germinal center of the brain that gives rise to these tumors. PACAP acts in these germinal cells by increasing cAMP and activating protein kinase A (PKA). Studies that began in *Drosophila* and were extended to vertebrates had indicated that protein kinase A (PKA) antagonizes HH signaling at the level of signaling intermediates. However, the importance of this interaction in human disease models has never been demonstrated. Our hypothesis in deleting the PACAP gene from *ptc1* mutant mice was that removal of this potential inhibitory influence on HH

pathway activity would cause an even higher and more rapid incidence of medulloblastoma. The findings of increased incidence and more rapid onset of tumors imply that secondary or concomitant genetic events leading to suppression of PKA activity may play a key role in transformation of neoplastic granular progenitor cells into medulloblastoma and perhaps in the induction of other tumors associated with overactive HH signaling.

To further reinforce our hypothesis that loss of PACAP would enhance activation of Shh pathway in tumors, we performed a set of gene expression analyses in tumors by real-time RT-PCR. This analysis revealed that the expression of three Shh target genes *gli1*, *N-myc* and *Bmi1* were increased 2- to 5-fold in tumors from DH mice compared to those from *ptc1*^{+/-} mice, whereas *Gli3* gene expression did not significantly differ. Previous studies reported that the former genes are induced by Shh in cerebellar granule precursor cells (Kenney et al., 2003; Leung et al., 2004; Wechsler-Reya and Scott, 1999), and are overexpressed in human MB (Leung et al., 2004; Reifenberger et al., 1998; Yokota et al., 2004). Furthermore, recent studies have shown the important role of Gli1 in MB formation (Kimura et al., 2005). Gene expression of the Notch facilitator MSH1 (Yokota et al., 2004), which is also




Fig. 4. PACAP receptor (PAC₁) gene expression in representative tumors and in an ectopic patch of proliferating EGL. (A) PACAP receptor PAC₁ gene expression in selected tumors from *ptc1* and PACAP/*ptc1* double heterozygous mice, determined by RT-PCR. The two bands correspond to the “hop” and “null” forms of PAC₁ mRNAs which putatively can couple the receptor to other signal transduction pathways, including PLC and MAP kinase in addition to PKA (Spengler et al., 1993). Genotype is indicated at the bottom. (B) Ki-67 fluorescent immunohistochemistry shows a hyperplastic region of proliferating cells on the surface of the cerebellum of a postnatal day 28 DH mouse. Section is counterstained with DAPI. (C) ³³P *in situ* hybridization and dark field illumination demonstrating that PACAP receptor (PAC₁) gene transcripts are abundant in the hyperplastic lesion. Ectopic hyperplastic region is indicated with arrows. PL = Purkinje layer. PAC₁ receptors are abundant in the ectopic lesion. In addition, PAC₁ gene expression is present in the Purkinje layer, and at low levels in the internal granular layer.

overexpressed in human MB, was increased in tumors from DH mice. Our results clearly demonstrated that the Shh target genes as well as MB markers (*gli1*, *N-myc* and *Bmi1*) were expressed at higher levels in tumors from DH mutants than in those from *ptc1*^{+/-} mice. This suggests that the reduction of PACAP in double-mutant mice maintains Shh pathway activity in tumors at a high level, or that a lack of PACAP during their formation results in tumors with higher Shh activity.

Because all tumors tested exhibited PAC₁ receptor gene expression (Fig. 4A), as did all derived cell lines (data not shown), we tested the ability of the latter to respond to PACAP. Five of six cell lines exhibited significant growth rate reduction when treated with PACAP (Table 2). The ability of PACAP to stimulate cAMP production was confirmed in the cell line selected for further analysis (#57). The antiproliferative action of PACAP in these cells was blocked by H89, a selective inhibitor of the cAMP-dependent protein kinase (PKA), indicating that PACAP action on these cells was probably mediated by the cAMP/PKA pathway. This is in line with our previous findings on PACAP/Shh interaction in cerebellar granule cell progenitors (Nicot et al., 2002), and reinforced the hypothesis that PACAP is an endogenous regulator of granular cell progenitors, and potentially plays a role in their transformation into MB, and/or on their rate of growth. We also measured the effect of PACAP on the Shh target gene *gli1* mRNA expression. PACAP also reduced *gli1* mRNA levels, an effect which was mimicked by forskolin, an inducer of cAMP production. A similar result was obtained using β-galactosidase reporter gene assay as an alternative method to evaluate

hedgehog pathway activity (data not shown). It would be interesting to know where in the Hh signaling pathway PKA acts in these cells. However, this is difficult to study because it has been reported that the Hh pathway becomes significantly repressed when MB tumor cells from *ptc1* mutant mice are placed in culture (Sasai et al., 2006). In agreement with that report, we found that proliferation and *gli1* gene expression were reduced by only 40–50% after treatment with the smoothed antagonist cyclopamine (data not shown). Thus, it remains uncertain where the PACAP/PKA and Hh pathways intersect in these cells.

The PACAP/*ptc1* DH mice generated here represent a unique new model for MB. Although combining *ptc1* mutations with *p53* mutations in mice results in an even higher incidence of MB tumors (Wetmore et al., 2001), the novelty of the PACAP/*ptc1* DH model is that the two targeted mutations appear to cooperate to derepress a common signaling pathway putatively involved in many human MBs, and to activate a number of other genes known to be overexpressed in human tumors. Moreover, the increased incidence of MB in *ptc1*^{+/-} mice due to loss of PACAP suggests that a heterotrimeric G protein-coupled receptor-mediated activation of PKA can antagonize a hedgehog pathway-driven process. However, the experiments reported here do not rule out the possibility that that loss of PACAP enhanced tumors in *ptc1* mice is due to a mechanism other than a reduction of PKA. PACAP is known to activate several other signaling pathways in parallel or downstream of cAMP, including pathways involving nitric oxide (Murthy et al., 1993), phospholipase C (Spengler et al., 1993), phospho-




Fig. 5. Gene expression in freshly resected MB tumors from *ptc1*^{+/-} vs. DH mice. Comparison of expression of several genes in tumors from *ptc1*^{+/-} vs. DH mice by real-time RT-PCR. Tumor samples from DH mice showed significant increases in *BMI1*, *MSH1*, *gli1*, and *N-myc*, when compared to tumors isolated from *ptc1* mutants (ANOVA, $p < 0.01$) or from wild-type C57BL/6J total cerebellum or isolated granular cell progenitors. Conversely, no differences were observed between groups when amplification was done with *gli3* primer sets. Values are expressed relative to the control gene *GAPDH*. The increased expressions of *Gli1*, and *BMI* were confirmed using β_2 -microglobulin mRNA as an alternative housekeeping mRNA control. Mean values are indicated with a horizontal line. Statistical analyses were performed using one-way ANOVA followed by pairwise comparison using Bonferroni ad hoc post-test when overall $p < 0.05$. GOI= gene of interest; CB=adult cerebellum; GC=cerebellar granule cells freshly isolated from postnatal day 6 mice as described in the Materials and methods.

tidylinositol 3-kinase (Straub and Sharp, 1996), and src (Koh, 1991). In addition, in some cell types PACAP has been shown to act through MAP kinase pathways (Barrie et al., 1997; Lelievre et al., 1998; Villalba et al., 1997), inhibition of the NF κ B cascade and Jak1/Jak2 phosphorylation (Delgado and Ganea, 1999, 2000).

Table 2
PACAP inhibition of DNA synthesis in several cell lines established from medulloblastoma tumors arising in *ptc1*^{+/-} and mice double heterozygous (DH) for *ptc1*^{+/-} and PACAP

Cell line	Genotype	Proliferation (% of control)
961	<i>ptc1</i> ^{+/-}	80±1.7*
1393	<i>ptc1</i> ^{+/-}	93±4.2 ^a
1395	<i>ptc1</i> ^{+/-}	74±6.2**
1713	<i>ptc1</i> ^{+/-}	56±2.6**
1717	<i>ptc1</i> ^{+/-}	48±6.2**
57	DH	68±3.5**

Statistically analyzed by ANOVA: * $p < 0.05$, ** $p < 0.001$, ^anot significant.

In any case, the significance PACAP in the pathogenesis of human MB remains to be explored. Most human MB tumors in one series were found to express receptors which bind both PACAP and the closely related peptide vasoactive intestinal peptide (Fruhwald et al., 1999). It is unknown if mutations in either PACAP or PACAP receptors are present in human MB tumors. With respect to the most common signaling pathway for PACAP (cAMP/PKA), a limited analysis of PKA genes showed no consistent LOH in a series of human MB tumors (Zurawel et al., 2000). However, PKA genes were not sequenced in this series, and other components of the cAMP signaling pathway, such as adenylate cyclases, and regulators of G protein signaling were not examined. The cAMP/PKA may also be important in modulating other signaling pathways in addition to Hh believed to be involved in the pathogenesis of MB. For example, several Wnt pathway genes have been implicated in medulloblastoma (reviewed in Pietsch et al., 2004). Different models systems indicate that PKA might act at several steps in this signaling pathway (Chen et al., 2005; Hino et al., 2005; Masai et al., 2005).




Fig. 6. Action of PACAP and Shh on proliferation and *gli1* gene expression in MB cell line #57. (A) cAMP induction by 1 μ M forskolin and by increasing the concentrations of PACAP. (B) Concentration-dependent antiproliferative action of PACAP-38 and blockade by 3 μ M of the PKA antagonist H89. Cells were treated for 6 h. (C) Long-term reduction in cell proliferation by daily addition of 10 nM PACAP. (D) Reduction in gene expression of *gli1* and *Math1* induced by 12-h treatment with 10 nM PACAP or 20 μ M forskolin. For panels B–D, three independent experiments were performed in triplicate. Results were consistent between experiments, and representative data are shown. Statistical analyses in panels B and D were performed with one-way ANOVA followed by pairwise comparison using Bonferroni ad hoc post-test (performed when overall $p < 0.05$). Significant differences at $*p < 0.05$, $**p < 0.01$ or $***p < 0.005$. Statistical analysis of data in panel C using ANOVA followed by Bonferroni ad hoc post test showed significant differences at $p < 0.001$.

Finally, PACAP receptors are expressed on multiple types of cancer (Waschek et al., 2006). Although mutations in the genes encoding PACAP or any of its receptor subtypes have not yet been genetically linked to any of these malignancies, it may be of interest to determine the relevance of a PACAP/Hh interaction in the pathogenesis of the growing list of tumors that appear to involve overactive Hh signaling (Berman et al., 2003; Kaye et al., 2004; Kubo et al., 2004; Stecca et al., 2005; Thayer et al., 2003; Watkins et al., 2003).

Acknowledgments

This present work was supported by the NIH grants CA110384, HD34475, HD04612 (J.W.), and CA121131 (L.L.), by the University of California at Los Angeles Neuro-Oncology Seed Grant Program, and by the Department of

Energy Cooperative Agreement Contract number DE-FC03-02ER63420. V.L. is a recipient of fellowship from INSERM/Fondation pour la Recherche Medicale (France).

References

- Aza-Blanc, P., Ramirez-Weber, F.A., Laget, M.P., Schwartz, C., Kornberg, T.B., 1997. Proteolysis that is inhibited by hedgehog targets cubitus interruptus protein to the nucleus and converts it to a repressor. *Cell* 89, 1043–1053.
- Baillie, G.S., Scott, J.D., Houslay, M.D., 2005. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. *FEBS Lett.* 579, 3264–3270.
- Barrie, A.P., Clohessy, A.M., Buensuceso, C.S., Rogers, M.V., Allen, J.M., 1997. Pituitary adenylyl cyclase-activating peptide stimulates extracellular signal-regulated kinase 1 or 2 (ERK1/2) activity in a Ras-independent, mitogen-activated protein Kinase/ERK kinase 1 or 2-dependent manner in PC12 cells. *J. Biol. Chem.* 272, 19666–19671.
- Berman, D.M., Karhadkar, S.S., Hallahan, A.R., Pritchard, J.I., Eberhart, C.G., Watkins, D.N., Chen, J.K., Cooper, M.K., Taipale, J., Olson, J.M., Beachy, D.P., 2003. Disruption of the *PACAP* gene promotes medulloblastoma in *ptc1* mutant mice. *Developmental Biology* (2007), doi:10.1016/j.ydbio.2007.10.031

- P.A., 2002. Medulloblastoma growth inhibition by hedgehog pathway blockade. *Science* 297, 1559–1561.
- Berman, D.M., Karhadkar, S.S., Maitra, A., Montes De Oca, R., Gerstenblith, M.R., Briggs, K., Parker, A.R., Shimada, Y., Eshleman, J.R., Watkins, D.N., Beachy, P.A., 2003. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. *Nature* 425, 846–851.
- Chen, Y., Cardinaux, J.R., Goodman, R.H., Smolik, S.M., 1999. Mutants of cubitus interruptus that are independent of PKA regulation are independent of hedgehog signaling. *Development* 126, 3607–3616.
- Chen, A.E., Ginty, D.D., Fan, C.M., 2005. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. *Nature* 433, 317–322.
- Chomczynski, P., Sacchi, N., 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. *Anal. Biochem.* 162, 156–159.
- Colwell, C.S., Michel, S., Itri, J., Rodriguez, W., Tam, J., Lelievre, V., Hu, Z., Waschek, J.A., 2004. Selective deficits in the circadian light response in mice lacking PACAP. *Am. J. Physiol.: Regul. Integr. Comp. Physiol.* 287, R1194–R1201.
- Corcoran, R.B., Scott, M.P., 2001. A mouse model for medulloblastoma and basal cell nevus syndrome. *J. Neurooncol.* 53, 307–318.
- Delgado, M., Ganea, D., 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. *J. Biol. Chem.* 274, 31930–31940.
- Delgado, M., Ganea, D., 2000. Inhibition of IFN-gamma-induced janus kinase-1–STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. *J. Immunol.* 165, 3051–3057.
- Ellison, D., 2002. Classifying the medulloblastoma: insights from morphology and molecular genetics. *Neuropathol. Appl. Neurobiol.* 28, 257–282.
- Epstein, D.J., Marti, E., Scott, M.P., McMahon, A.P., 1996. Antagonizing cAMP-dependent protein kinase A in the dorsal CNS activates a conserved sonic hedgehog signaling pathway. *Development* 122, 2885–2894.
- Fruhwald, M.C., O'Dorisio, M.S., Fleitz, J., Pietsch, T., Reubi, J.C., 1999. Vasoactive intestinal peptide (VIP) and VIP receptors: gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood. *Int. J. Cancer* 81, 165–173.
- Fukuda, K., Yasugi, S., 2002. Versatile roles for sonic hedgehog in gut development. *J. Gastroenterol.* 37, 239–246.
- Goodrich, L.V., Milenkovic, L., Higgins, K.M., Scott, M.P., 1997. Altered neural cell fates and medulloblastoma in mouse patched mutants. *Science* 277, 1109–1113.
- Gray, S.L., Cummings, K.J., Jirik, F.R., Sherwood, N.M., 2001. Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. *Mol. Endocrinol.* 15, 1739–1747.
- Hammerschmidt, M., Bitgood, M.J., McMahon, A.P., 1996. Protein kinase A is a common negative regulator of hedgehog signaling in the vertebrate embryo. *Genes Dev.* 10, 647–658.
- Hashimoto, H., Shintani, N., Tanaka, K., Mori, W., Hirose, M., Matsuda, T., Sakaue, M., Miyazaki, J., Niwa, H., Tashiro, F., Yamamoto, K., Koga, K., Tomimoto, S., Kunugi, A., Suetake, S., Baba, A., 2001. Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). *Proc. Natl. Acad. Sci. U. S. A.* 98, 13355–13360.
- Hino, S., Tanji, C., Nakayama, K.I., Kikuchi, A., 2005. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. *Mol. Cell. Biol.* 25, 9063–9072.
- Jia, J., Tong, C., Wang, B., Luo, L., Jiang, J., 2004. Hedgehog signalling activity of Smoothened requires phosphorylation by protein kinase A and casein kinase I. *Nature* 432, 1045–1050.
- Kayed, H., Kleeff, J., Keleg, S., Guo, J., Ketterer, K., Berberat, P.O., Giese, N., Esposito, I., Giese, T., Buchler, M.W., Friess, H., 2004. Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. *Int. J. Cancer* 110, 668–676.
- Kenney, A.M., Cole, M.D., Rowitch, D.H., 2003. *Nmyc* upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. *Development* 130, 15–28.
- Kimura, H., Kawatani, M., Ito, E., Ishikawa, K., 2003. Effects of pituitary adenylate cyclase-activating polypeptide on facial nerve recovery in the guinea pig. *Laryngoscope* 113, 1000–1006.
- Kimura, H., Stephen, D., Joyner, A., Curran, T., 2005. *Gli1* is important for medulloblastoma formation in *Ptc1*^{+/-} mice. *Oncogene* 24, 4026–4036.
- Kleihues, P., Cavenee, W.K., International Agency for Research on Cancer, International Society of Neuropathology, 1998. Pathology and Genetics of Tumours of the Nervous System. International Agency for Research on Cancer, Lyon.
- Koh, S.W., 1991. Signal transduction through the vasoactive intestinal peptide receptor stimulates phosphorylation of the tyrosine kinase pp60c-src. *Biochem. Biophys. Res. Commun.* 174, 452–458.
- Kubo, M., Nakamura, M., Tasaki, A., Yamanaka, N., Nakashima, H., Nomura, M., Kuroki, S., Katano, M., 2004. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. *Cancer Res.* 64, 6071–6074.
- Lelievre, V., Pineau, N., Du, J., Wen, C.H., Nguyen, T., Janet, T., Muller, J.M., Waschek, J.A., 1998. Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. A novel VIP-independent action of PHI via MAP kinase. *J. Biol. Chem.* 273, 19685–19690.
- Lelievre, V., Caigneaux, E., Muller, J.M., Falcon, J., 2000. Extracellular adenosine deprivation induces epithelial differentiation of HT29 cells: evidence for a concomitant adenosine A(1)/A(2) receptor balance regulation. *Eur. J. Pharmacol.* 391, 21–29.
- Leung, C., Lingbeek, M., Shakhova, O., Liu, J., Tanger, E., Saremaslani, P., Van Lohuizen, M., Marino, S., 2004. *Bmi1* is essential for cerebellar development and is overexpressed in human medulloblastomas. *Nature* 428, 337–341.
- Li, W., Ohlmeyer, J.T., Lane, M.E., Kalderon, D., 1995. Function of protein kinase A in hedgehog signal transduction and *Drosophila* imaginal disc development. *Cell* 80, 553–562.
- Lum, L., Beachy, P.A., 2004. The hedgehog response network: sensors, switches, and routers. *Science* 304, 1755–1759.
- Masai, I., Yamaguchi, M., Tonou-Fujimori, N., Komori, A., Okamoto, H., 2005. The hedgehog–PKA pathway regulates two distinct steps of the differentiation of retinal ganglion cells: the cell-cycle exit of retinoblasts and their neuronal maturation. *Development* 132, 1539–1553.
- Murthy, K.S., Zhang, K.M., Jin, J.G., Grider, J.R., Makhlof, G.M., 1993. VIP-mediated G protein-coupled Ca²⁺ influx activates a constitutive NOS in dispersed gastric muscle cells. *Am. J. Physiol.* 265, G660–G671.
- Nicot, A., Lelievre, V., Tam, J., Waschek, J.A., DiCicco-Bloom, E., 2002. Pituitary adenylate cyclase-activating polypeptide and sonic hedgehog interact to control cerebellar granule precursor cell proliferation. *J. Neurosci.* 22, 9244–9254.
- Nielsen, H.S., Hannibal, J., Fahrenkrug, J., 1998. Expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the postnatal and adult rat cerebellar cortex. *NeuroReport* 9, 2639–2642.
- Pietsch, T., Taylor, M.D., Rutka, J.T., 2004. Molecular pathogenesis of childhood brain tumors. *J. Neurooncol.* 70, 203–215.
- Poh, A., Karunaratne, A., Kolle, G., Huang, N., Smith, E., Starkey, J., Wen, D., Wilson, I., Yamada, T., Hargrave, M., 2002. Patterning of the vertebrate ventral spinal cord. *Int. J. Dev. Biol.* 46, 597–608.
- Reifenberger, J., Wolter, M., Weber, R.G., Megahed, M., Ruzicka, T., Lichter, P., Reifenberger, G., 1998. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. *Cancer Res.* 58, 1798–1803.
- Sasai, K., Romer, J.T., Lee, Y., Finkelstein, D., Fuller, C., McKinnon, P.J., Curran, T., 2006. Shh pathway activity is down-regulated in cultured medulloblastoma cells: implications for preclinical studies. *Cancer Res.* 66, 4215–4222.
- Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P.H., Journot, L., 1993. Differential signal transduction by five splice variants of the PACAP receptor. *Nature* 365, 170–175.

- Stecca, B., Mas, C., Ruiz i Altaba, A., 2005. Interference with HH-GLI signaling inhibits prostate cancer. *Trends Mol. Med.* 11, 199–203.
- Straub, S.G., Sharp, G.W., 1996. A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide. *J. Biol. Chem.* 271, 1660–1668.
- Tao, Y., Black, I.B., DiCicco-Bloom, E., 1997. In vivo neurogenesis is inhibited by neutralizing antibodies to basic fibroblast growth factor. *J. Neurobiol.* 33, 289–296.
- Thayer, S.P., di Magliano, M.P., Heiser, P.W., Nielsen, C.M., Roberts, D.J., Lauwers, G.Y., Qi, Y.P., Gysin, S., Fernandez-del Castillo, C., Yajnik, V., Antoniu, B., McMahon, M., Warshaw, A.L., Hebrok, M., 2003. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. *Nature* 425, 851–856.
- Tiecke, E., Turner, R., Sanz-Ezquerro, J.J., Warner, A., Tickle, C., 2007. Manipulations of PKA in chick limb development reveal roles in digit patterning including a positive role in sonic hedgehog signaling. *Dev. Biol.* 305, 312–324.
- Vaudry, D., Gonzalez, B.J., Basille, M., Yon, L., Fournier, A., Vaudry, H., 2000. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. *Pharmacol. Rev.* 52, 269–324.
- Villalba, M., Bockaert, J., Journot, L., 1997. Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. *J. Neurosci.* 17, 83–90.
- Waschek, J.A., 2002. Multiple actions of pituitary adenylate cyclase activating peptide in nervous system development and regeneration. *Dev. Neurosci.* 24, 14–23.
- Waschek, J.A., Casillas, R.A., Nguyen, T.B., DiCicco-Bloom, E.M., Carpenter, E.M., Rodriguez, W.I., 1998. Neural tube expression of pituitary adenylate cyclase-activating peptide (PACAP) and receptor: potential role in patterning and neurogenesis. *Proc. Natl. Acad. Sci. U. S. A.* 95, 9602–9607.
- Waschek, J.A., DiCicco-Bloom, E., Nicot, A., Lelievre, V., 2006. Hedgehog signaling: new targets for GPCRs coupled to cAMP and protein kinase A. *Ann. N. Y. Acad. Sci.* 1070, 120–128.
- Watkins, D.N., Berman, D.M., Burkholder, S.G., Wang, B., Beachy, P.A., Baylin, S.B., 2003. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. *Nature* 422, 313–317.
- Wechsler-Reya, R.J., Scott, M.P., 1999. Control of neuronal precursor proliferation in the cerebellum by sonic hedgehog. *Neuron* 22, 103–114.
- Wetmore, C., Eberhart, D.E., Curran, T., 2000. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. *Cancer Res.* 60, 2239–2246.
- Wetmore, C., Eberhart, D.E., Curran, T., 2001. Loss of *p53* but not ARF accelerates medulloblastoma in mice heterozygous for patched. *Cancer Res.* 61, 513–516.
- Yokota, N., Mainprize, T.G., Taylor, M.D., Kohata, T., Loreto, M., Ueda, S., Dura, W., Grajkowska, W., Kuo, J.S., Rutka, J.T., 2004. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. *Oncogene* 23, 3444–3453.
- Zurawel, R.H., Allen, C., Chiappa, S., Cato, W., Biegel, J., Cogen, P., de Sauvage, F., Raffel, C., 2000. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. *Genes Chromosomes Cancer* 27, 44–51.